CASE REPORT article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1329756
Treatment of hepatocellular carcinoma with gluteus medius metastasis: a case report and a literature review
Provisionally accepted
- 1Department of Oncology, First People’s Hospital of Guangyuan, Guangyuan, China, Guangyuan, China
- 2Department of Obstetrics and Gynecology, The First People's Hospital of Guangyuan, Guangyuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hepatocellular carcinoma (HCC) accounts for 85% ~ 90% of primary liver cancer (PLC). Due to the occult nature of HCC, most patients present at an advanced stage at the time of initial diagnosis and have a poor prognosis. With regards to systemic therapy, targeted therapy and immunotherapy are the center of clinical research at present. With regards to local treatment, surgical resection, radiofrequency ablation, hepatic artery chemoembolization, radiotherapy are commonly employed. Interstitial brachytherapy is commonly used in the treatment of cervical and genitourinary cancers. In this case, interstitial brachytherapy was used to treat a gluteus medius muscle metastasis from PLC with good local control and symptom relief.
Keywords: Hepatocellular Carcinoma, Muscle metastasis, Radiotherapy, Interstitial brachytherapy, Bulky tumor
Received: 29 Oct 2023; Accepted: 31 Mar 2025.
Copyright: © 2025 Li, Luo, Zhang, Sun and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yanxin Li, Department of Oncology, First People’s Hospital of Guangyuan, Guangyuan, China, Guangyuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.